Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...